| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
25 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-40 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Apexigen Inc is a biopharmaceutical company that specializes in the discovery and development of novel therapeutics to treat cancer and other diseases. They utilize a proprietary antibody discovery and directed evolution platform called APXiMAB™ to create high-quality monoclonal antibodies. These antibodies target specific pathways involved in disease progression, immune modulation, and tissue remodeling.
Apexigen has a strong focus on immuno-oncology, developing therapies that harness the body's immune system to fight cancer. They have several product candidates in various stages of clinical development, including APX005M, which is being studied as a potential treatment for solid tumors and hematologic malignancies.
The company collaborates with pharmaceutical partners and academic institutions to advance their research and development efforts. Their goal is to bring innovative therapies to patients and improve outcomes in areas of unmet medical need.
Company Address: 900 Industrial Road San Carlos 94070 CA
Company Phone Number: 931-6236 Stock Exchange / Ticker: NASDAQ APGN
|
%
0.27% 